Oral high-dose medroxyprogesterone acetate causes adrenal suppression in patients with breast cancer.
D000284:Administration, Oral; D000302:Adrenal Cortex / Q000378:metabolism*; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy*; D003864:Depression, Chemical; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D012636:Secretory Rate / Q000187:drug effects
D000324:Adrenocorticotropic Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone